The actor denounced new vaccination rules in California, but insists he is not anti-vaccine.» Read More
Susquehanna's Stacey Gilbert thinks biotech could be due for a pullback. She lays out an options strategy to protect your biotech holdings.
CNBC's Meg Tirrell reports the latest on Stifel downgrading Biogen and Pfizer making a positive move. CNBC's Brian Sullivan and Melissa Lee weigh in on the biotech sector.
Jean-Jacques Bienaime, BioMarin Pharmaceuticals CEO, discusses his company's bull run and new drugs to treat rare diseases, including Duchenne muscular dystrophy.
Biogen has seen its value quadruple to more than $100 billion on the back of its successful multiple sclerosis drugs. Now it has new ambitions.
Big-name biotech stocks have been on a tear, but some "Fast Money" traders warned the run may not continue.
Why the biotech space still has room to run, with John Stoltzfus, Oppeneimer, and the "Closing Bell" panel.
Biotechs and small caps are the top performers on Wall Street, with the health-care subsector up about 8 percent for the week.
As the biotech sector and names such as Biogen continue to surge, finding value is becoming increasingly difficult, an expert says.
David Seaburg, Cowen & Co., and Ari Wald, Oppenheimer, join "Power Lunch" to discuss the biotech rally.
Yaron Werber, Citi Investment Research, discusses recent Biogen activity and his investment outlook on the stock. "This stock has upside," says Werber.
CNBC's Dominic Chu reports which biotech stocks are fueling the run higher in the iShares Nasdaq Biotech ETF, the IBB.
CNBC's Meg Tirrell reports the biotech company got better than expected results regarding its Alzheimer's drug.
CNBC's Meg Tirrell has the latest results on the biotech's Alzheimer's drug.
A Biogen Alzheimer's drug showed a significant slowing of the disease's hallmark cognitive declines.
Celgene's phase 2 study of its experimental Crohn's disease pill was published in The New England Journal of Medicine. Phase 3 is expected to start this year, reports CNBC's Meg Tirrell.
As Biogen Idec gets set to reveal new data on its Alzheimer's drug, BIIB037, investors should be prepared for a big move either way.
Studies of a new class of cholesterol-lowering drugs signal that they can reduce by half the risk of heart attack.
Here are the stocks to watch heading out of this weekend's American College of Cardiology conference in San Diego.
Biotechs are on a tear. Akiva Felt, Oppenheimer, provides perspective on the biotech boom, and his favorite picks in the space.
A destructive insect's growing resistance to genetically modified corn seeds is costing American farmers as much as $2 billion annually.
Get the best of CNBC in your inbox